Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer

Journal of Clinical Oncology

Volumn 25, Issue 30, 2007, Pages 4787-4792

  Kulke, Matthew H ^a   Blaszkowsky, Lawrence S ^a   Ryan, David P ^a   Clark, Jeffrey W ^a   Meyerhardt, Jeffrey A ^a   Zhu, Andrew X ^a   Enzinger, Peter C ^a   Kwak, Eunice L ^a   Muzikansky, Alona ^a   Lawrence, Colleen ^a   Fuchs, Charles S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; QUINAZOLINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DESQUAMATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSGEUSIA; EDEMA; FATIGUE; FEMALE; GENE MUTATION; HAND FOOT SYNDROME; HUMAN; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PANCREAS CANCER; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; STOMATITIS; SURVIVAL TIME; TREATMENT RESPONSE; VOMITING; ADENOCARCINOMA; GENETICS; LIVER TUMOR; METABOLISM; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; SALVAGE THERAPY; SURVIVAL RATE; TUMOR RECURRENCE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PANCREATIC NEOPLASMS; PROGNOSIS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SALVAGE THERAPY; SURVIVAL RATE;

EID: 36048940287     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.11.8521     Document Type: Article

References (40)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2006. CA Cancer J Clin 56:106-130, 2006
2. Burris H, Moore M, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997
3. Hidalgo M, Castellano D, Paz-Ares L: Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 17:585-592, 1999
4. Rocha Lima C, Savarese D, Bruckner H, et al: Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 20:1182-1191, 2002
5. Heinemann V, Wilke H, Mergenthaler HG, et al: Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol 11:1399-1403, 2000
6. Louvet C, Andre T, Lledo G, et al: Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: Final results of a GERCOR multicenter phase II study. J Clin Oncol 20:1512-1518, 2002
7. Berlin J, Catalano P, Thomas J, et al: A phase III study of gemcitabine in combination with 5-FU versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20:3270-3275, 2002
8. Heinemann V, Quietzsch D, Gieseler F, et al: A phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic carcinoma. Proc Am Soc Clin Oncol 22:250, 2003 (abstr 1003)
9. Rocha Lima C, Rotche R, Jeffery M, et al: A randomized phase 3 study comparing efficacy and safety of gemcitabine and irinotecan to gemcitabine alone in patients with locally advanced or metastatic pancreatic cancer who have not received prior systemic therapy. Proc Am Soc Clin Oncol 22:251, 2003 (abstr 1005)
10. Louvet C, Labianca R, Hammel P, et al: Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23:3509-3516, 2005
11. Cartwright T, Cohn A, Varkey J, et al: Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 20: 160-164, 2002
12. Hess V, Salzberg M, Borner M, et al: Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: A phase I/II trial. J Clin Oncol 21:66-68, 2003
13. Scheithauer W, Schull B, Ulrich-Pur H, et al: Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: A randomized phase II trial. Ann Oncol 14:97-104, 2003
14. Herrmann R, Bodoky G, Ruhstaller T, et al: Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: A randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 25:2212-2217, 2007
15. Cunningham D, Chau I, Stocken D, et al: Phase III randomised comparison of gemcitabine with gemcitabine plus capecitabine in patients with advanced pancreatic cancer. Eur J Cancer 3:4, 2005 (suppl)
16. Moyer JD, Barbacci EG, Iwata KK, et al: Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 57:4838-4848, 1997
17. Johnson JR, Cohen M, Sridhara R, et al: Approval summary for erlotinib for treatment of patients with locally advanced or metastatic nonsmall cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res 11: 6414-6421, 2005
18. Soulieres D, Senzer NN, Vokes EE, et al: Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22:77-85, 2004
19. Hidalgo M, Siu L, Nemunaitis J: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19:3267-3279, 2001
20. Dragovich T, McCoy S, Fenoglio-Preiser CM, et al: Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 24:4922-4927, 2006
21. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
22. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004
23. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966, 2007
24. Meyerhardt JA, Zhu AX, Enzinger PC, et al: Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. J Clin Oncol 24:1892-1897, 2006
25. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
26. Kwak EL, Jankowski J, Thayer SP, et al: Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res 12:4283-4287, 2006
27. Immervoll H, Hoem D, Kugarajh K, et al: Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: Lack of mutations in the BRAF and EGFR genes. Virchows Arch 448:788-796, 2006
28. Eberhard D, Johnson B, Amler L, et al: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23:5900-5909, 2005
29. Tsuchihashi Z, Khambata-Ford S, Hanna N, et al: Responsiveness to cetuximab without mutations in EGFR. N Engl J Med 353:208-209, 2005
30. Philip P, Benedetti J, Fenoglio-Preiser C, et al: Phase III study of gemcitabine plus cetuximab versus gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma: SWOG S0205 study. J Clin Oncol 25:199s, 2007 (suppl; abstr LBA4509)
31. Boeck S, Weigang-Kohler K, Fuchs M, et al: Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: A multicenter phase II trial. Ann Oncol 18:745-751, 2007
32. Demols A, Peeters M, Polus M, et al: Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: A phase II study. Br J Cancer 94:481-485, 2006
33. Reni M, Pasetto L, Aprile G, et al: Raltitrexedeloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. Br J Cancer 94:785-791, 2006
34. Tsavaris N, Kosmas C, Skopelitis H, et al: Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study. Invest New Drugs 23:369-375, 2005
35. Jacobs A, Burris H, Rivkin S, et al: A randomized phase III study of rubitican vs best choice in 409 patients with refractory pancreatic cancer report from a North-American multi-center study. J Clin Oncol 22:316s, 2004 (suppl; abstr 4013)
36. Cantore M, Rabbi C, Fiorentini G, et al: Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer. Oncology 67:93-97, 2004
37. Milella M, Gelibter A, Di Cosimo S, et al: Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer 101:133-138, 2004
38. Ulrich-Pur H, Raderer M, Verena Kornek G, et al: Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br J Cancer 88:1180-1184, 2003
39. Kozuch P, Grossbard M, Barzdins A, et al: Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncross-resistant treatment for chemotherapy refractory metastatic pancreatic cancer. Oncologist 6:488-495, 2001
40. Oettle H, Arnold D, Esser M, et al: Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs 11:635-638, 2000